• New ways found to tackle deadly South American hemorrhagic fever viruses

    New World hemorrhagic fevers are nasty, serious, and often fatal diseases which cause Ebola-like symptoms; most outbreaks occur in rural regions of Bolivia, Venezuela, Argentina, and Brazil; the outbreaks of New World hemorrhagic fever tend to be brief and brutal, with mortality rates of 20 to 30 percent; scientists have discovered exactly how one type of New World hemorrhagic fever virus latches onto and infects human cells, offering a much-needed lead toward new treatments

  • Foodborne illness costs U.S. $152 billion annually

    The most comprehensive study of the subject finds that the cumulative cost to Americans of foodborne illnesses is $152 billion annually; the cost per case for an individual is $1,850 on average; the Centers for Disease Control and Prevention (CDC) estimates that there are 76 million new cases of food-related illness in the United States every year, resulting in 5,000 deaths and 325,000 hospitalizations

  • New way to control disease-spreading mosquitoes: Prevent them from urinating

    Aedes aegypti mosquitoes transmit the virus that causes dengue fever, putting 40 percent of the world’s population at risk of catching the disease, and causing 50 million to 100 million infections and 22,000 deaths annually; researchers find a way to control the mosquitoes: Prevent them from urinating as they feed on blood

  • Useful tree provides low-cost water purification method for developing world

    A billion people across Asia, Africa, and Latin America are estimated to rely on untreated surface water sources for their daily water needs; of these, some two million are thought to die from diseases caught from contaminated water every year, with the majority of these deaths occurring among children under five years of age; seeds from the Moringa oleifera tree, can produce a 90.00 percent to 99.99 percent bacterial reduction in previously untreated water

  • iBio to license vaccine production facility using green plant technology

    iBio will license the iBioLaunch platform to G-Con, LLC, a private Texas company; the “GreenVax Project” uses Nicotiana plants grown hydroponically; the green plant technology platform holds the promise of shortening vaccine production from months to weeks

  • PharmAthene says its anthrax vaccine is superior to first-generation vaccine

    PharmAthene’s anthrax vaccine, called SparVax, will require three doses over a 60-day period — the first-generation vaccine requires five doses over 18 months; a course of treatment with the currently available vaccine costs about $125; SparVax would cost just $45 a treatment

  • $150 million anthrax vaccine contract goes to firm with close Democratic Party ties

    The Department of Health and Human Services (HHS) announced on the evening of 29 December that it was awarding PharmAthene $150 million to develop and produce an anthrax vaccine; FOXNews notes the strong ties to the Democratic Party of senior company executives

  • Europe would be better with a generic, rather than disease-specific, pandemic response plan

    New study argues that the emphasis in Europe on disease-specific emergency plans utilized by most European countries could cost precious time and resources; “Countries and organizations invest enormous resources in developing plans for specific diseases, which may not even present a threat in the future,” the study says

  • U.S. anthrax response undermined by public ignorance, lack of confidence in government

    A Harvard School of Public Health’s survey found that nearly 40 percent of respondents who said they would likely accept antibiotic pills distributed from public health authorities after an anthrax attack also said they would not start taking them immediately; about 35 percent indicated they would hold onto the drugs until they knew for certain they had been exposed to anthrax

  • Montana State team developing new way to fight influenza, bioterrorism threats

    Researchers develop aerosol spray containing tiny protein cages that will activate an immune response in the lungs; the protein cages trigger the rapid production of lymphoid tissue in the lung; the technology could be used to prevent or treat a range of pulmonary diseases including influenza; it might counter bioterrorism threats, such as airborne microbes

  • U.S.-China farm trade tensions grow

    U.S. companies, steel producers, and unions have filed dozens of domestic trade complaints against Chinese imports; economists say the imports of food based on labor intensive crops are next in line for trade friction between the United States and China

  • Farmers, ranchers urged to be aware of agroterrorism

    South Dakota’s U.S. Attorney Brendan Johnson says all aspects of agriculture can be targets of terrorists, but Johnson said meat production is the most vulnerable; “Livestock are the number one target for terrorists attacking the agriculture system…. If you want to get a bunch of cattle sick at once, it’s not rocket science on how to do it”

  • The digital revolution offers new ways to fight epidemics

    There are more than 100 H1N1 apps for iPhone — and several other apps dedicated to identifying, locating, and reporting the outbreak of epidemics; these digital tools could help people take preventive measures earlier than otherwise would have been the case, but they also open the door to mass panic from unreliable or false reports

  • Killing malaria bugs dead with laser

    Mosquito-killing laser demonstrated; if bed nets are the low-tech solution to combat the deadly malaria — caused by a parasite transmitted when certain mosquitoes bite people — the laser is a high-tech one; the laser detection is so precise, it can specify the species, and even the gender, of the mosquito being targeted

  • Immunovaccine offers enhanced anthrax vaccine candidate

    Currently, to provide protection from anthrax, individuals receive a 6-dose regime with three injections given two weeks apart, followed by three additional injections given at 6, 12, and 18 months; annual booster injections of the vaccine are recommended thereafter; Canadian company Immunovaccine says it developed a method to cut this arduous regimen by half